{"nctId":"NCT01583218","briefTitle":"Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)","startDateStruct":{"date":"2012-03"},"conditions":["Venous Thromboembolism (VTE)"],"count":7513,"armGroups":[{"label":"Betrixaban","type":"EXPERIMENTAL","interventionNames":["Drug: Betrixaban"]},{"label":"Enoxaparin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enoxaparin"]}],"interventions":[{"name":"Betrixaban","otherNames":[]},{"name":"Enoxaparin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* men and non-pregnant, non-breastfeeding women\n* anticipated to be severely immobilized for at least 24 hours after randomization\n* hospitalized with one of the following\n\n  * congestive heart failure\n  * acute respiratory failure,\n  * acute infection without septic shock,\n  * acute rheumatic disorders\n  * acute ischemic stroke with lower extremity hemiparesis or hemi paralysis\n\nExclusion Criteria:\n\n* a condition requiring prolonged anticoagulation or anti-platelets\n* active bleeding or at high risk of bleeding\n* contraindication to anticoagulant therapy\n* general conditions in which subjects are not suitable to participate in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary Emboli (PE), VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3","description":"mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.70","spread":null},{"groupId":"OG001","value":"7.18","spread":null}]}]}]},{"type":"PRIMARY","title":"mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3","description":"mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.70","spread":null},{"groupId":"OG001","value":"6.02","spread":null}]}]}]},{"type":"PRIMARY","title":"mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, VTE-related Death, or Asymptomatic Proximal DVT, Through Visit 3","description":"mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.43","spread":null},{"groupId":"OG001","value":"5.99","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing Major Bleeding Through Seven Days After Discontinuation of All Study Medication","description":"Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":null},{"groupId":"OG001","value":"0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"mITT Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3","description":"mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"1.90","spread":null}]}]}]},{"type":"SECONDARY","title":"mITT Cohort 2: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3","description":"mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"1.45","spread":null}]}]}]},{"type":"SECONDARY","title":"mITT: Percentage of Participants Experiencing the Composite Event of Symptomatic DVT, Non-fatal PE, or VTE-related Death, Through Visit 3","description":"mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":null},{"groupId":"OG001","value":"1.45","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":657,"n":3716},"commonTop":["Constipation","Urinary tract infection","Insomnia","Hypokalaemia","Hypertension"]}}}